Hematology continues to evolve at pace, with innovative therapies transforming the management of both malignant and non-malignant blood disorders. At APLUSA, we have developed deep expertise in this area through decades of specialized market research and patient-level data collection. Our market trackers, patient chart studies, and advanced methodologies shed light on physician decision-making, treatment sequencing, and market adoption in conditions ranging from lymphomas to bleeding disorders.
Whether supporting early-stage strategy, preparing for launch, or monitoring in-market performance, we help clients cut through complexity to anticipate trends and identify opportunities.
Core focus areas
- Multiple Myeloma (MM)
- Leukemia (CLL/AML)
- Lymphoma (DLBCL/MCL/FL/MZL/HL/ALCL)
- Myelofibrosis (MF)
- Myelodysplastic Syndrome (MDS)
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Beta-Thalassemia
- Hemophilia A & B
- ITP (Immune Thrombocytopenic Purpura)








